Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply. Visuri I, Eriksson C, Olen O, Cao Y, et al. Aliment Pharmacol Ther 2021;54:848-849.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Visuri I, Eriksson C, Olen O, Cao Y, et al. Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply. Aliment Pharmacol Ther 2021;54:848-849.
PMID: 34425010